Janus Henderson Group PLC bought a new position in Cytokinetics, Incorporated (NASDAQ:CYTK) in the second quarter, according to the company in its most recent disclosure with the SEC. The fund bought 2,684,930 shares of the biopharmaceutical company’s stock, valued at approximately $32,488,000. Janus Henderson Group PLC owned 5.00% of Cytokinetics, at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. State of Alaska Department of Revenue bought a new stake in Cytokinetics, in the 2nd quarter worth approximately $109,000. Municipal Employees Retirement System of Michigan bought a new stake in Cytokinetics, in the 2nd quarter worth approximately $132,000. Bank of America Corp DE grew its position in Cytokinetics, by 36.8% in the 1st quarter. Bank of America Corp DE now owns 12,571 shares of the biopharmaceutical company’s stock worth $162,000 after purchasing an additional 3,383 shares during the period. BNP Paribas Arbitrage SA grew its position in Cytokinetics, by 4,464.4% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 13,328 shares of the biopharmaceutical company’s stock worth $161,000 after purchasing an additional 13,036 shares during the period. Finally, Parametric Portfolio Associates LLC grew its position in Cytokinetics, by 1.4% in the 1st quarter. Parametric Portfolio Associates LLC now owns 13,333 shares of the biopharmaceutical company’s stock worth $171,000 after purchasing an additional 189 shares during the period. 71.50% of the stock is owned by institutional investors and hedge funds.

Cytokinetics, Incorporated (NASDAQ:CYTK) opened at 15.40 on Tuesday. Cytokinetics, Incorporated has a 1-year low of $8.77 and a 1-year high of $17.20. The company’s 50 day moving average is $14.65 and its 200-day moving average is $13.88. The stock’s market cap is $826.46 million.

Cytokinetics, (NASDAQ:CYTK) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.03). Cytokinetics, had a negative return on equity of 14.15% and a negative net margin of 16.00%. The firm had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $5.28 million. Equities research analysts forecast that Cytokinetics, Incorporated will post ($2.51) earnings per share for the current fiscal year.

CYTK has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of Cytokinetics, from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research report on Tuesday, July 11th. BidaskClub upgraded shares of Cytokinetics, from a “sell” rating to a “hold” rating in a research note on Thursday, July 13th. Morgan Stanley initiated coverage on shares of Cytokinetics, in a research note on Monday, July 31st. They set an “overweight” rating and a $24.00 price target on the stock. HC Wainwright set a $26.00 price target on shares of Cytokinetics, and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Finally, Cowen and Company reiterated a “buy” rating and set a $19.00 price target on shares of Cytokinetics, in a research note on Friday, August 4th. Three investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $21.64.

TRADEMARK VIOLATION WARNING: This piece was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://theolympiareport.com/2017/10/17/janus-henderson-group-plc-takes-32-49-million-position-in-cytokinetics-incorporated-cytk.html.

In related news, insider Caryn Gordon Mcdowell sold 13,181 shares of the stock in a transaction on Friday, October 6th. The shares were sold at an average price of $15.49, for a total transaction of $204,173.69. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Bradley Paul Morgan sold 118,330 shares of the stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $15.00, for a total transaction of $1,774,950.00. Following the sale, the senior vice president now directly owns 63,107 shares in the company, valued at $946,605. The disclosure for this sale can be found here. Insiders have sold 177,990 shares of company stock worth $2,628,996 over the last three months. 7.20% of the stock is currently owned by insiders.

Cytokinetics, Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Institutional Ownership by Quarter for Cytokinetics, (NASDAQ:CYTK)

Receive News & Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.